Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial

(2015) L. Kappos et al.   NEUROLOGY

Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide

(2014) Emanuela Colombo et al.   ANNALS OF NEUROLOGY

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

(2014) Alice Laroni et al.   BMC Neurology

The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination

(2014) A Slowik et al.   BRITISH JOURNAL OF PHARMACOLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

(2014) Bruce Hughes et al.   Multiple Sclerosis and Related Disorders

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

(2014) Ludwig Kappos et al.   Multiple Sclerosis and Related Disorders

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

(2013) Jeffrey A. Cohen et al.   JOURNAL OF NEUROLOGY

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

(2013) Ralf Gold et al.   JOURNAL OF NEUROLOGY

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

(2013) G Francis et al.   Multiple Sclerosis Journal

Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis

(2013) Marco A. Zarbin et al.   OPHTHALMOLOGY

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

(2010) Volker Brinkmann et al.   NATURE REVIEWS DRUG DISCOVERY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

(2009) David Marsolais et al.   NATURE REVIEWS DRUG DISCOVERY

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY